These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36451820)

  • 21. Factor B and C4b2a Autoantibodies in C3 Glomerulopathy.
    Hauer JJ; Shao D; Zhang Y; Nester CM; Smith RJH
    Front Immunol; 2019; 10():668. PubMed ID: 31024533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simple immunofixation test for induced C3 degradation in disease states (including C3 nephritic factor) and its correlation with kidney biopsy.
    Sarkar E; Roberts EG; Wallage MJ; Unsworth DJ; Lock RJ
    J Immunol Methods; 2014 Jan; 402(1-2):71-5. PubMed ID: 24239583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of C3 Nephritic Factor by Hemolytic Assay.
    Chabannes M; Frémeaux-Bacchi V; Chauvet S
    Methods Mol Biol; 2021; 2227():147-158. PubMed ID: 33847940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of C3 Nephritic Factors by ELISA.
    Skattum L
    Methods Mol Biol; 2019; 1901():177-182. PubMed ID: 30539576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of complement in C3 glomerulopathy.
    Zipfel PF; Skerka C; Chen Q; Wiech T; Goodship T; Johnson S; Fremeaux-Bacchi V; Nester C; de Córdoba SR; Noris M; Pickering M; Smith R
    Mol Immunol; 2015 Sep; 67(1):21-30. PubMed ID: 25929733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies.
    Skattum L; Mårtensson U; Sjöholm AG
    J Intern Med; 1997 Dec; 242(6):455-64. PubMed ID: 9437406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-factor B autoantibody in dense deposit disease.
    Strobel S; Zimmering M; Papp K; Prechl J; Józsi M
    Mol Immunol; 2010 Apr; 47(7-8):1476-83. PubMed ID: 20193965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C3 Glomerulopathy.
    Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
    Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
    J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A C3 convertase assay for nephritic factor functional activity.
    Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
    J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the alternative pathway of complement activation in glomerular diseases.
    Łukawska E; Polcyn-Adamczak M; Niemir ZI
    Clin Exp Med; 2018 Aug; 18(3):297-318. PubMed ID: 29450785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.
    Miller EC; Chase NM; Densen P; Hintermeyer MK; Casper JT; Atkinson JP
    Clin Immunol; 2012 Dec; 145(3):241-50. PubMed ID: 23117396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.
    Zhao F; Afonso S; Lindner S; Hartmann A; Löschmann I; Nilsson B; Ekdahl KN; Weber LT; Habbig S; Schalk G; Kirschfink M; Zipfel PF; Skerka C
    Front Immunol; 2019; 10():1030. PubMed ID: 31214159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control.
    Prohászka Z; Nilsson B; Frazer-Abel A; Kirschfink M
    Immunobiology; 2016 Nov; 221(11):1247-58. PubMed ID: 27475991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C3 glomerulopathy: A new complement-based entity.
    de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
    Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.